RNA interference inhibits high mobility group box 1 by lipopolysaccharide- activated murine macrophage RAW 264.7 secretion

Journal of Surgical Research

Volumn 168, Issue 2, 2011, Pages

  Hu, Han Chung ^a,b,c   Wang, Ting Ya ^a   Chen, Yung Che ^a,b   Wang, Chin Chou ^a   Lin, Meng Chih ^a,b,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c XIAMEN CHANG GUNG HOSPITAL   (China)

Author keywords

(TNF ); high mobility group box 1 (HMGB 1); interleukin 6 (IL 6); short interfering RNAs (siRNAs); transforming growth factor (TGF ); tumor necrosis factor

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NAFAMSTAT MESILATE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; INFLAMMATION; MACROPHAGE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; RNA INTERFERENCE;

ANIMALS; CELL LINE; CYTOKINES; DOWN-REGULATION; GUANIDINES; HMGB1 PROTEIN; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERINE PROTEINASE INHIBITORS;

EID: 79955814220     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2011.02.019     Document Type: Article

References (32)

1. Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem 1973;38:14.
2. Mosevitsky MI, Novitskaya VA, Iogannsen MG, et al. Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur J Biochem 1989;185:303.
3. Czura CJ, Tracey KJ. Targeting high mobility group box 1 as a late-acting mediator of inflammation. Crit Care Med 2003;31:S46.
4. Yang H, Wang H, Czura CJ, et al. HMGB1 as a cytokine and therapeutic target. J Endotoxin Res 2002;8:469.
5. Andersson U, Erlandsson-Harris H, Yang H, et al. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 2002;72:1084.
6. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cell triggers inflammation. Nature 2002;418:191.
7. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248.
8. Wang H, Yang H, Czura CJ, et al. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001;164:1768.
9. Mantell LL, Parrish WR, Ulloa L. HMGB-1 as a therapeutic target for infectious and inflammatory disorders. Shock 2006;25:4.
10. Yamada S, Maruyama I. HMGB1, a novel inflammatory cytokine. Clin Chim Acta 2007;375:36.
11. Stern D, Yan SD, Yan SF, et al. Receptor for advanced glycation endproducts: A multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002;54:1615.
12. Czura CJ, Yang H, Amella CA, et al. HMGB1 in the immunology of sepsis (not septic shock) and arthritis. Adv Immunol 2004;84:181.
13. Dinarello CA. The interleukin-1 family: 10 Years of discovery. FASEB J 1994;8:1314.
14. Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004;4:378.
15. Yang H, Ochani M, Li JH, et al. Reversing established sepsis with antagonists of endogenous HMGB1. Proc Natl Acad Sci USA 2004;101:296.
16. Yang H, Wang H, Czura CJ, et al. The cytokine activity of HMGB1. J Leukoc Biol 2005;78:1.
17. Wang H, Vishnubhakat JM, Bloom O, et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1 stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999;126:389.
18. Lutz W, Stetkiewicz J. High mobility group box 1 protein as a late-acting mediator of acute lung inflammation. Int J Occup Med Environ Health 2004;17:245.
19. Kalinina N, Agrotis A, Antropova Y, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: Role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004;24:2320.
20. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494.
21. Sioud M. Therapeutic siRNAs. Trends Pharmacol Sci 2004;25:22.
22. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431:371.
23. Hagiwara S, Iwasaka H, Matumoto S, et al. Nafamostat mesilate inhibits high-mobility group box 1 by lipopolysaccharide stimulation in murine macrophage RAW 264.7. Shock 2007;27:429.
24. Noguchi S, Nakatsuka M, Konishi H, et al. Nafamostat mesilate suppresses NF-kB activation and NO overproduction in LPS-treated macrophages. Int Immunopharmacology 2003;3:1335.
25. Hagiwara S, Iwasaka H, Noguchi T. Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury. J Anesth 2007;21:164.
26. Kokkola R, Sundberg E, Ulfgren AK, et al. High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis. Arthritis Rheum 2002;46:2598.
27. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003;9:517.
28. Arcaroli J, Yum HK, Kupfner J, et al. Role of p38 MAP kinase in the development of acute lung injury.Clin Immunol 2001;101:211.
29. Li J, Wang H, Mason JM, et al. Recombinant HMGB-1 with cytokine-stimulating activity. J Immunol Method 2004;289:211.
30. Tang D, Shi Y, Jang L, et al. Heat shock response inhibits release of high mobility group box 1 protein induced by endotoxin in murine macrophages. Shock 2005;23:434.
31. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987;330:662.
32. Cook G, Campbell JD, Carr CE, et al. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol 1999;66:981.